# MR Antagonist and LSD1

> **NCT04840342** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Hypertension
- Mineralocorticoid Excess

## Interventions

- **DRUG:** Eplerenone
- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT04840342
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-03
- **Primary completion:** 2025-09-15
- **Final completion:** 2026-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840342, "MR Antagonist and LSD1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04840342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*